Graham Capital Management L.P. Acquires Shares of 50,949 Kura Oncology, Inc. (NASDAQ:KURA)

Graham Capital Management L.P. purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 50,949 shares of the company's stock, valued at approximately $444,000. Graham Capital Management L.P. owned 0.07% of Kura Oncology at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in KURA. Virtus ETF Advisers LLC raised its stake in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after buying an additional 3,061 shares in the last quarter. Harbor Advisors LLC acquired a new position in Kura Oncology during the fourth quarter valued at $87,000. E Fund Management Co. Ltd. acquired a new stake in Kura Oncology during the 4th quarter worth about $90,000. Corton Capital Inc. purchased a new position in Kura Oncology during the 4th quarter valued at about $99,000. Finally, Optimize Financial Inc acquired a new position in shares of Kura Oncology in the 4th quarter valued at about $100,000.

Kura Oncology Price Performance

KURA stock traded down $0.04 during trading on Thursday, hitting $6.17. The company had a trading volume of 77,414 shares, compared to its average volume of 1,181,586. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The company has a market cap of $533.73 million, a P/E ratio of -2.61 and a beta of 0.50. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $23.48. The company has a fifty day moving average price of $6.35 and a two-hundred day moving average price of $8.61.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analysts' expectations of $39.08 million. Equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday, April 8th. Wall Street Zen lowered Kura Oncology from a "buy" rating to a "hold" rating in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Kura Oncology in a research report on Monday, April 28th. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Finally, UBS Group cut their price objective on Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 6th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $24.50.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.